Alex Biese

In patients with operable, newly diagnosed brain metastases, GammaTile was associated with reduction in the risk of tumor recurrence or death.

Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.

The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free survival.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

Home-based supervised physical activity has no major impact on fatigue and quality of life for patients with metastatic cancer receiving oral targeted therapy.

For patients with pancreatic cancer, this is a guide to the basics you need to know about this disease.

Addressing spirituality and religion can potentially help patients with gynecologic cancers, researchers have found.

The FDA granted fast track designation to NG-350A for the treatment of patients with mismatch repair-proficient locally advanced rectal cancer.

CURE spoke with Betsy Hamlin, who was treated with Keytruda Qlex in a clinical trial after being diagnosed with melanoma.

The FDA has granted breakthrough therapy designation to ficerafusp alfa with Keytruda for some patients with head and neck squamous cell carcinoma.

CURE spoke with Dr. Komal Jhaveri about the findings of the EMBER-3 clinical trial.

CURE spoke with melanoma survivor Betsy Hamlin about her experience with subcutaneous Keytruda in a clinical trial.

From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.

Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.

The FDA has approved Libtayo for the postsurgical treatment of adults with cutaneous squamous cell carcinoma.

In locally recurrent inoperable or metastatic TNBC, Datroway resulted in improvement in overall survival and progression-free survival.

The New Jersey retreat is free for women during and two years after cancer treatment.

The author and advocate, facing leukemia for the third time in 15 years, sat down for an interview with CURE.

Neuroblastoma is the most common cancer in infants and most commonly occurs in children younger than 5 years old.

The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.

A diagnosis of esophageal cancer can bring up many questions and concerns. Our goal is to provide you with clear, accurate and educational information.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Napo Pharmaceuticals applied for orphan drug designation for Mytesi to treat diarrhea in patients with breast cancer and brain metastases on targeted therapy.

Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.

Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.

Utidelone, previously received orphan drug designation from the FDA for the treatment of breast cancer brain metastases and gastric cancer.

Women with a history of cervical cancer are nearly twice as likely to develop anal cancer as members of the general population, according to researchers.

CURE spoke with Amanda Davis at the John Theurer Cancer Center in Hackensack, New Jersey.

CURE spoke with nurse and breast cancer survivor Amanda Davis at the John Theurer Cancer Center.